We are advising InSilico Medicine on the financing

Davis Polk is advising InSilico Medicine in connection with its $35 million Series D2 financing, bringing the total Series D financing to $95 million. The Series D2 round is led by Prosperity7, the diversified growth fund of Aramco Ventures. Other global investors with expertise in the biopharmaceutical and life sciences sectors also participated.

Insilico Medicine, a clinical stage end-to-end artificial intelligence driven drug discovery company, is connecting biology, chemistry and clinical trials analysis using next-generation artificial intelligence systems. The company has developed artificial intelligence platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

Prosperity7 Ventures is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, a global integrated energy and chemicals company.

The Davis Polk corporate team includes partners James C. Lin, Miranda So and Howard Zhang and registered foreign lawyers Michael Zhuoran Xu and Yi-Ping Chang. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.